1450 related articles for article (PubMed ID: 29197254)
1. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
[TBL] [Abstract][Full Text] [Related]
2. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
[TBL] [Abstract][Full Text] [Related]
3. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins.
Fox KM; Tai MH; Kostev K; Hatz M; Qian Y; Laufs U
Clin Res Cardiol; 2018 May; 107(5):380-388. PubMed ID: 29273856
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan.
Teramoto T; Uno K; Miyoshi I; Khan I; Gorcyca K; Sanchez RJ; Yoshida S; Mawatari K; Masaki T; Arai H; Yamashita S
Atherosclerosis; 2016 Aug; 251():248-254. PubMed ID: 27419905
[TBL] [Abstract][Full Text] [Related]
6. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
7. Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.
Kristensen MS; Green A; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Larsen ML; Ersbøll AK
BMC Cardiovasc Disord; 2020 Jul; 20(1):336. PubMed ID: 32660429
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
Morieri ML; Avogaro A; Fadini GP;
Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
[TBL] [Abstract][Full Text] [Related]
9. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
10. Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.
Ferrières J; Rouyer MV; Lautsch D; Ashton V; Ambegaonkar BM; Brudi P; Gitt AK;
Arch Cardiovasc Dis; 2017 Mar; 110(3):167-178. PubMed ID: 28209375
[TBL] [Abstract][Full Text] [Related]
11. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan.
Olufade T; Zhou S; Anzalone D; Kern DM; Tunceli O; Cziraky MJ; Willey VJ
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473405
[TBL] [Abstract][Full Text] [Related]
12. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).
Danchin N; Almahmeed W; Al-Rasadi K; Azuri J; Berrah A; Cuneo CA; Karpov Y; Kaul U; Kayıkçıoğlu M; Mitchenko O; Ruiz AJ; Aguilar Salinas CA; Santos RD; Mercier F; Blom D;
Eur J Prev Cardiol; 2018 Jul; 25(10):1087-1094. PubMed ID: 29771156
[TBL] [Abstract][Full Text] [Related]
13. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS).
Blom DJ; Raal F; Amod A; Naidoo P; Lai YE;
Cardiovasc J Afr; 2019 Jan/Feb 23; 30(1):15-23. PubMed ID: 30720848
[TBL] [Abstract][Full Text] [Related]
14. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
[TBL] [Abstract][Full Text] [Related]
15. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe.
Ferrieres J; De Ferrari GM; Hermans MP; Elisaf M; Toth PP; Horack M; Brudi P; Lautsch D; Bash LD; Baxter CA; Ashton V; Ambegaonkar B; Gitt AK
Eur J Prev Cardiol; 2018 Dec; 25(18):1966-1976. PubMed ID: 30335504
[TBL] [Abstract][Full Text] [Related]
16. Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
Marrett E; Zhao C; Zhang NJ; Zhang Q; Ramey DR; Tomassini JE; Tershakovec AM; Neff DR
Vasc Health Risk Manag; 2014; 10():237-46. PubMed ID: 24851051
[TBL] [Abstract][Full Text] [Related]
17. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
[TBL] [Abstract][Full Text] [Related]
20. Trends in Statin Use 2009-2015 in a Large Integrated Health System: Pre- and Post-2013 ACC/AHA Guideline on Treatment of Blood Cholesterol.
Harrison TN; Scott RD; Cheetham TC; Chang SC; Hsu JY; Wei R; Ling Grant DS; Boklage SH; Romo-LeTourneau V; Reynolds K
Cardiovasc Drugs Ther; 2018 Aug; 32(4):397-404. PubMed ID: 30062465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
